#### **TRANSITION OF CARE FORM (TOCF)**

# FOR UZEDY® (RISPERIDONE) EXTENDED-RELEASE INJECTABLE SUSPENSION

Please fax **COMPLETED** form to **1-877-228-4190** Questions? Call **1-800-887-8100** (9AM to 8PM ET, M-F)

#### teva | Shared Solutions

Teva Shared Solutions® can help you plan for starting and staying on UZEDY. We can help you-or your caregiver-figure out your insurance, Medicare, or Medicaid coverage and find financial assistance options. Shared Solutions can also help you find an injection site near your home or work. Plus, we provide over-the-phone nurse support for questions or concerns you or your caregiver may have about UZEDY.

USE THIS FORM TO ENROLL PATIENTS IN SHARED SOLUTIONS **TO SEEK HELP WITH TRANSITION OF CARE AND WHEN PRESCRIBING UZEDY**.

1	SITE OF CARE					•	REQUI	RED FOR PROCESSING	
FROM	<b>DISCHARGING INPATIENT SITE INFORMATION:</b> Site Name:				NEXT SITE OF CARE INFORMATION: Site Name:				
	Address:				Address:				
	City:	Sto	ate: Zip:		City:		Stat	State: Zip:	
	Site Contact Name:	Co	ntact Phone:		Site Contact Name:		Con	Contact Phone:	
	Prescriber Name:	NF	1#:		Site Fax:		Date	Date of Appointment:	
	Date of Discharge:				Prescriber Name:		NPI:	NPI#:	
					Type of setting:  (Hospital) Outpatient (Care) Center  Community/Behavioral Mental Health Center (CMHC/BMHC)			Provider office Other:	
2	PATIENT INFORMATION						REQUI	RED FOR PROCESSING	
First Name:		MI: Last Name:				DOB (MM/DD/YYYY):	Gender:	Male Fema	
ddı	ress:		City:			State:		Zip:	
Home Phone:		Mobile Phone:			Email:				
ALTERNATIVE PATIENT CONTACT/CAREGIVER N		R NAME:	Relationship to Patient:		Phone: Email:				
_ >	DATIENT AUTHORIZATION						DEOU		
nay eva luth irote	PATIENT AUTHORIZATION  norize my healthcare providers, pharmacie ment, care management, prescriptions, ar ort program service provider (collectively det to my prescribed medication and/or nance coverage, which may include allowin led, determining my eligibility for and coorcluct administration training and education; sess activities; (viii) contacting me by direct ry behalf in connection with carrying out the receive financial remuneration from the mc Shared Solutions, P.O. Box 4280, Gaithers orization will remain in effect until the Proected by federal privacy law. I understand not sign this Authorization. However, if I do	inufacturer of burg, MD, 20 gram ends. I that my treati	your medication. I underst 885-4280, but my cancell understand that once my ment, payment for treatm	tand the lation w information	at I may cancel this ill not apply to any ation is disclosed, prance enrollment	Authorization at any time, by information already disclosed it may be subject to redisclo, or eligibility for insurance be	on related to provide so providers or providers or providers or providers or providers or providers on tact information that the theorem writing to a pursuant sure by the nefits will reaccopy of	Teva, Attn: Authorization to this Authorization. The recipients and no long to the directly affected	
PATI	ENT OR PERSONAL REPRESENTATIVE SI	GNATURE:					Date:		
	ned by someone other than the patient, plete the following information:	Name:				Relationship/legal	authority	to sign on patient beh	
	By checking this box, I authorize Teva, its prerecorded calls and/or messages), and to develop future products, services, and instructions on the communication. Opting i	electronic me programs. I u	essages for marketing and understand that I may cho	d promo oose to	otional purposes, no longer receive	to conduct market research o e further communications fro	r surveys, m Teva by	and to use my informa following the unsubsc	

### **TRANSITION OF CARE FORM (TOCF)**

## FOR UZEDY® (RISPERIDONE) EXTENDED-RELEASE INJECTABLE SUSPENSION Please fax COMPLETED form to 1-877-228-4190 $\mid$ Questions? Call 1-800-887-8100 (9AM to 8PM ET, M-F)

Patient Name:			D	DOB (MM/DD/YYYY):				
4. DIAGNOSIS AND HISTORY								
ICD-10 Code:								
F20.0 Paranoid schizophrenia F20.1 Disorgai	nized schizophrenia	a F20.2 Catatoni	c schizophrenia	F20.3 Und	ifferentiated schizophr	enia		
F20.5 Residual schizophrenia F20.89 Other	schizophrenia	F20.9 Unspecif	ied schizophrenia	Other:				
Date of last UZEDY administration:								
	JZEDY dosage	Once monthly:			every 2 months:	0 10 10		
	50 mg/0.14 mL							
accide care seeming								
5 PATIENT INSURANCE INFORMATIO	N							
Must include copy of insurance card and pharmacy benefit PRIMARY INSURANCE: Medicare Medicare Policyholder Name:		Military Benefits [ DOB (MM/DD/Y	Commercial/Pri	vate Insurance onship to Patien	I do not have	insurance		
Insurance Name:	Phone:		ID/Policy #:		Group #:			
SECONDARY INSURANCE NAME (IF APPLICABLE):	Phone:		ID/Policy #:		Group #:			
Policyholder Name:		DOB (MM/DD/YYYY):			Relationship to Patient:			
6 PREFERRED PHARMACY								
Preferred Pharmacy:	Ī	Phone:		Fax:				
Address:	(	City:		State:	Zip:			
Already prescribed UZEDY to above pharmacy on								
. ,	Date							

